Doktor axborotnomasi 2026, №1 (122)
Subject of the article
METFORMIN IN GESTATIONAL DIABETES MELLITUS: A REVIEW OF CURRENT EVIDENCE ON BENEFITS AND POTENTIAL RISKS (185-190)
Authors
N. N. Shavazi, M. R. Ilkhomova
Institution
Samarkand state medical university, Samarkand, Uzbekistan
Abstract
Gestational diabetes mellitus is associated with an increased risk of adverse maternal and perinatal outcomes. The use of metformin in GDM remains under discussion because the drug crosses the placental barrier and evidence regarding potential long-term effects of intrauterine exposure is limited. Analysis of randomized trials, meta-analyses, and clinical guidelines indicates that metformin provides glycemic control comparable to insulin and is associated with less gestational weight gain, although some patients require additional insulin therapy to achieve target glycemic levels. Short-term perinatal outcomes in most studies do not differ significantly. However, the issue of long-term met abolic effects in offspring remains unresolved and warrants further prospective research.
Key words
gestational diabetes mellitus, metformin, insulin therapy, glycemic control, perinatal outcomes, long-term effects, pregnancy, safety profile.
Literature
1. American Diabetes Association. Standards of Medical Care in Diabetes — Section “Diabetes in Pregnancy”. Dia betes Care. 2023–2024. 2. Bellamy L., Casas J.P., Hingorani A.D., Williams D. Type 2 diabetes after gestational diabetes: a systematic re view and meta-analysis. Lancet. PMID: 19465232 DOI: 10.1016/S0140-6736(09)60731-5 3. Cochrane Pregnancy and Childbirth Group. Oral anti-diabetic pharmacological therapies for treating women with gestational diabetes mellitus. Cochrane Database of Systematic Reviews. 2017. 4. Denice S Feig, Lois E Donovan, Bernard Zinman, J Johanna Sanchez, Elizabeth Asztalos. Metformin in women with type 2 diabetes in pregnancy (MiTy): a multicentre, international, randomised, placebo-controlled trial. PMID: 32946820 DOI: 10.1016/S2213-8587(20)30310-7 5. Denice S Feig, J Johanna Sanchez, Kellie E Murphy, Elizabeth Asztalos, Bernard Zinman. Outcomes in children of women with type 2 diabetes exposed to metformin versus placebo during pregnancy (MiTy Kids): a 24-month follow-up of the MiTy randomised controlled trial. PMID: 36746160 DOI: 10.1016/S2213-8587(23)00004-9 6. Goh JE, Sadler L, Rowan J. Metformin for gestational diabetes in routine clinical practice. Diabet Med. 2011 Sep;28(9):1082-7. doi: 10.1111/j.1464-5491.2011.03361.x. PMID: 21679232. 7. International Diabetes Federation. IDF Diabetes Atlas. 10th ed. 2021. PMID: 35914061 8. Ijäs H, Vääräsmäki M, Morin-Papunen L, Keravuo R, Ebeling T, Saarela T, Raudaskoski T. Metformin should be considered in the treatment of gestational diabetes: a prospective randomised study. BJOG. 2011 Jun;118(7):880 5. doi: 10.1111/j.1471-0528.2010.02763.x. Epub 2010 Nov 18. PMID: 21083860. 9. JANET A. ROWAN, FRACP A Trial in Progress: Gestational Diabetes. Treatment with metformin compared with insulin (the Metformin in Gestational Diabetes [MiG] trial) PMID: 17596475. DOI: 10.2337/dc07-s219 10. Mayadunne, T., Saadati, S., Asmelash, D., Mason, T., Vanky, E., Teede, H., & Mousa, A. (2025). Long-term ef fects of metformin on offspring health: A review of current evidence and future directions. Diabetes, obesity & metabolism, 27 Suppl 3(Suppl 3), 48–63. https://doi.org/10.1111/dom.16418 11. Recent systematic and narrative reviews on metformin in pregnancy (2023–2025). Wiley Online Library (selected publications). 12. Rowan J.A., Hague W.M., Gao W., et al. Metformin versus Insulin for the Treatment of Gestational Diabetes. PMID: 18463376 DOI: 10.1056/NEJMoa0707193 13. Janet A Rowan 1, Elaine C Rush, Victor Obolonkin, Malcolm Battin, Trecia Wouldes, William M Hague. Metfor min in gestational diabetes: the offspring follow-up (MiG TOFU): body composition at 2 years of age. PMID: 21949222 PMCID: PMC3177748 DOI: 10.2337/dc11-0660 14. Janet A Rowan, Elaine C Rush, Lindsay D Plank, Jun Lu, Victor Obolonkin, Suzette Coat, William M Hague Met formin in gestational diabetes: the offspring follow-up (MiG TOFU): body composition and metabolic outcomes at 7-9 years of age. PMID: 29682291 PMCID: PMC5905785 DOI: 10.1136/bmjdrc-2017-000456 15. Singh, A. K., & Singh, R. (2015). Metformin in gestational diabetes: An emerging contender. Indian journal of endocrinology and metabolism, 19(2), 236–244. https://doi.org/10.4103/2230-8210.149317 16. Tarry-Adkins JL, Aiken CE, Ozanne SE. Neonatal, infant, and childhood growth following metformin versus insu lin treatment for gestational diabetes: A systematic review and meta-analysis. PLoS Med. 2019 Aug 6;16 (8):e1002848. doi: 10.1371/journal.pmed.1002848. PMID: 31386659; PMCID: PMC6684046. 17. Vera Tocci, Maria Mirabelli, Alessandro Salatino, Luciana Sicilia, Stefania Giuliano, Francesco S Brunetti, Euse bio Chiefari, Giovambattista De Sarro, Daniela P Foti, Antonio Brunetti. Metformin in Gestational Diabetes Melli tus: To Use or Not to Use, That Is the Question. PMID: 37765126 PMCID: PMC10537239 DOI: 10.3390/ ph16091318